These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 33832512)

  • 1. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
    Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
    J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
    Kawanishi M; Fujita M; Karasawa K
    Breast Cancer (Auckl); 2022; 16():11782234221080553. PubMed ID: 35340889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.
    Tian C; Wei Y; Li J; Huang Z; Wang Q; Lin Y; Lv X; Chen Y; Fan Y; Sun P; Xiang R; Chang A; Yang S
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA.
    Wang C; Luo H; Chen X; Zhang Y; Lu D; Liu X; Yin F; Li S; Kong L; Wang X
    Bioorg Chem; 2023 Oct; 139():106683. PubMed ID: 37379778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer.
    Wu C; Peng S; Pilié PG; Geng C; Park S; Manyam GC; Lu Y; Yang G; Tang Z; Kondraganti S; Wang D; Hudgens CW; Ledesma DA; Marques-Piubelli ML; Torres-Cabala CA; Curry JL; Troncoso P; Corn PG; Broom BM; Thompson TC
    Mol Cancer Ther; 2021 Sep; 20(9):1680-1691. PubMed ID: 34158347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer.
    Fang W; Wang J; Ma X; Shao N; Ye K; Zhang D; Shi C; Luo L
    Int J Nanomedicine; 2023; 18():6001-6019. PubMed ID: 37901361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
    Yi J; Liu C; Tao Z; Wang M; Jia Y; Sang X; Shen L; Xue Y; Jiang K; Luo F; Liu P; Cheng H
    EBioMedicine; 2019 May; 43():225-237. PubMed ID: 30898650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
    Suzuki Y; Wenwen W; Ohta T; Hayashi SI
    Breast Cancer; 2022 Jan; 29(1):77-91. PubMed ID: 34346034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
    Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
    Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
    [No Abstract]   [Full Text] [Related]  

  • 14. Metallointercalator [Ru(dppz)
    Yusoh NA; Leong SW; Chia SL; Harun SN; Rahman MBA; Vallis KA; Gill MR; Ahmad H
    ACS Chem Biol; 2020 Feb; 15(2):378-387. PubMed ID: 31898884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
    Li Y; Wang Y; Zhang W; Wang X; Chen L; Wang S
    Sci Rep; 2021 Feb; 11(1):4774. PubMed ID: 33637776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib-Resistant
    Biegała Ł; Gajek A; Marczak A; Rogalska A
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    Guney Eskiler G; Ozman Z; Haciefendi A; Cansaran-Duman D
    Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):1031-1041. PubMed ID: 36598514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.